MCID: ADD001
MIFTS: 62

Addison's Disease malady

Categories: Rare diseases, Endocrine diseases, Genetic diseases

Aliases & Classifications for Addison's Disease

Aliases & Descriptions for Addison's Disease:

Name: Addison's Disease 12 50 14
Addison Disease 12 50 56 41 42 69
Adrenal Gland Hypofunction 50 69
Adrenal Hypoplasia 50 29
Addison Disease, Chronic Adrenal Insufficiency 12
Autoimmune Primary Adrenal Insufficiency 69
Addison's Disease Due to Autoimmunity 69
Primary Adrenocortical Insufficiency 12
Hypoadrenocorticism, Familial 12
Hypoadrenocorticism Familial 50
Autoimmune Addison's Disease 56
Classic Addison's Disease 56
Primary Addison's Disease 56
Primary Hypoadrenalism 12
Autoimmune Adrenalitis 56
Addisons Disease 52
Adrenal Aplasia 50

Characteristics:

Orphanet epidemiological data:

56
addison disease
Prevalence: 1-5/10000,1-5/10000 (Europe); Age of onset: All ages; Age of death: any age;

HPO:

32
addison's disease:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 56  
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:13774
ICD10 33 E27.1
MeSH 42 D000224
NCIt 47 C26689
Orphanet 56 ORPHA85138
MESH via Orphanet 43 D000224
UMLS via Orphanet 70 C0001403 C0271737
ICD10 via Orphanet 34 E27.1
UMLS 69 C0001403

Summaries for Addison's Disease

MedlinePlus : 41 your adrenal glands are just above your kidneys. the outside layer of these glands makes hormones that help your body respond to stress and regulate your blood pressure and water and salt balance. addison disease happens if the adrenal glands don't make enough of these hormones. a problem with your immune system usually causes addison disease. the immune system mistakenly attacks your own tissues, damaging your adrenal glands. other causes include infections and cancer. symptoms include weight loss muscle weakness fatigue that gets worse over time low blood pressure patchy or dark skin lab tests can confirm that you have addison disease. if you don't treat it, it can be fatal. you will need to take hormone pills for the rest of your life. if you have addison disease, you should carry an emergency id. it should say that you have the disease, list your medicines and say how much you need in an emergency. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Addison's Disease, also known as addison disease, is related to x-linked adrenal hypoplasia congenita and autoimmune addison disease, and has symptoms including arthralgia, constipation and fatigue. An important gene associated with Addison's Disease is ABCD1 (ATP Binding Cassette Subfamily D Member 1), and among its related pathways/superpathways are Insulin secretion and G alpha (s) signalling events. The drugs Epinephrine and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, skin and testes, and related phenotypes are Increased transferrin (TF) endocytosis and endocrine/exocrine gland

Disease Ontology : 12 An adrenal cortical hypofunction that is characterized by insufficient steroid hormone production by the adrenal glands.

NIH Rare Diseases : 50 addison's disease is a condition that occurs when the adrenal glands do not produce enough of their hormones. this condition can be caused by damage to the adrenal glands, autoimmune conditions, and certain genetic conditions. some of the symptoms include changes in blood pressure, chronic diarrhea, darkening of the skin, paleness, extreme weakness, fatigue, nausea and vomiting, salt craving, and weight loss. treatment with replacement corticosteroids usually controls the symptoms. last updated: 4/28/2011

Related Diseases for Addison's Disease

Diseases in the Addison's Disease family:

Autoimmune Addison Disease

Diseases related to Addison's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 99)
id Related Disease Score Top Affiliating Genes
1 x-linked adrenal hypoplasia congenita 12.4
2 autoimmune addison disease 12.2
3 adrenoleukodystrophy 11.7
4 autoimmune polyendocrine syndrome, type ii 11.4
5 achalasia-addisonianism-alacrimia syndrome 11.0
6 autoimmune polyendocrinopathy syndrome , type i, with or without reversible metaphyseal dysplasia 11.0
7 adrenal hypoplasia, congenital, with hypogonadotropic hypogonadism 10.8
8 autoimmune polyendocrine syndrome type 1 10.7
9 noonan-like syndrome with loose anagen hair 10.3 AIRE CTLA4
10 cleft lip palate-tetraphocomelia 10.3 CYP21A2 POMC
11 neutral lipid storage disease with myopathy 10.3 CTLA4 PTPN22
12 ataxia, spastic, 5, autosomal recessive 10.3 MC2R POMC
13 hypogonadism mitral valve prolapse mental retardation 10.2 POMC REN
14 glossopharyngeal nerve neoplasm 10.2 POMC REN
15 endometrial mixed adenocarcinoma 10.2 POMC REN
16 benign peritoneal mesothelioma 10.2 CYP21A2 MC2R POMC
17 cervical spinal canal and spinal cord meningioma 10.2 CYP21A2 STAR
18 cytomegalovirus retinitis 10.2 REN STAR
19 shaken baby syndrome 10.2 DDC REN
20 intermittent squint 10.2 CRH POMC
21 phaeohyphomycosis 10.2 AIRE CYP21A2 DDC
22 breast secretory carcinoma 10.1 CRH POMC
23 complement component 8 deficiency 10.1 AIRE CTLA4 CYP21A2 PTPN22
24 diabetes insipidus, nephrogenic 10.1 MC2R POMC
25 borderline personality disorder 10.1 CYP17A1 CYP21A2
26 nonparalytic poliomyelitis 10.1 CRH POMC
27 bent bone dysplasia syndrome 10.1 CYP17A1 CYP21A2
28 adrenal hypoplasia, congenital, with absent pituitary luteinizing hormone 10.1
29 familial glucocorticoid deficiency 10.1
30 inherited isolated adrenal insufficiency due to partial cyp11a1 deficiency 10.1
31 congenital adrenal hypoplasia of maternal cause 10.1
32 cytomegalic congenital adrenal hypoplasia 10.1
33 periodontosis 10.1 AIRE CTLA4 MC2R PTPN22
34 adrenal cortical adenocarcinoma 10.1 CRH CYP21A2 POMC
35 dacryoadenitis 10.1 CRH POMC
36 hypogonadism cardiomyopathy 10.1 CRH POMC
37 dyt1 early-onset isolated dystonia 10.1 CYP17A1 CYP21A2 POMC
38 sphingolipidosis 10.1 CYP17A1 CYP21A2 POMC
39 astroblastoma 10.1 CRH POMC REN
40 early-onset parkinson disease 10.1 CRH POMC
41 hypoadrenalism 10.1
42 immune system organ benign neoplasm 10.1 CRH POMC REN
43 pelvic muscle wasting 10.1 CYP17A1 CYP21A2 POMC
44 fatty liver disease 10.1 CRH POMC REN
45 endocrine organ benign neoplasm 10.0 CRH POMC REN
46 distal monosomy 14q 10.0 CYP11A1 CYP21A2 POMC REN
47 calcinosis 10.0 CRH POMC REN
48 clear cell adenocarcinoma 10.0 CYP17A1 POMC REN
49 cowden syndrome 1 10.0 CYP11A1 STAR
50 primary biliary cirrhosis 10.0 CYP11A1 CYP17A1 CYP21A2

Graphical network of the top 20 diseases related to Addison's Disease:



Diseases related to Addison's Disease

Symptoms & Phenotypes for Addison's Disease

Human phenotypes related to Addison's Disease:

56 32 (show top 50) (show all 58)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthralgia 56 32 Occasional (29-5%) HP:0002829
2 constipation 56 32 Very frequent (99-80%) HP:0002019
3 fatigue 56 32 Very frequent (99-80%) HP:0012378
4 seizures 56 32 Occasional (29-5%) HP:0001250
5 vertigo 56 32 Occasional (29-5%) HP:0002321
6 abdominal pain 56 32 Very frequent (99-80%) HP:0002027
7 diarrhea 56 32 Very frequent (99-80%) HP:0002014
8 nausea and vomiting 56 32 Very frequent (99-80%) HP:0002017
9 muscle weakness 56 32 Very frequent (99-80%) HP:0001324
10 salt craving 56 32 Occasional (29-5%) HP:0030083
11 dry skin 56 32 Occasional (29-5%) HP:0000958
12 failure to thrive 56 32 Very frequent (99-80%) HP:0001508
13 delayed puberty 56 32 Occasional (29-5%) HP:0000823
14 type i diabetes mellitus 56 32 Occasional (29-5%) HP:0100651
15 hypoglycemia 56 32 Occasional (29-5%) HP:0001943
16 hyperuricemia 56 32 Frequent (79-30%) HP:0002149
17 weight loss 56 32 Very frequent (99-80%) HP:0001824
18 hashimoto thyroiditis 56 32 Occasional (29-5%) HP:0000872
19 vitiligo 56 32 Occasional (29-5%) HP:0001045
20 celiac disease 56 32 Occasional (29-5%) HP:0002608
21 hypoparathyroidism 56 32 Occasional (29-5%) HP:0000829
22 anorexia 56 32 Very frequent (99-80%) HP:0002039
23 hyponatremia 56 32 Frequent (79-30%) HP:0002902
24 hypercalcemia 56 32 Occasional (29-5%) HP:0003072
25 thymoma 56 32 Very rare (<4-1%) HP:0100522
26 renal salt wasting 56 32 Frequent (79-30%) HP:0000127
27 adrenal hypoplasia 56 32 Occasional (29-5%) HP:0000835
28 increased circulating renin level 56 32 Frequent (79-30%) HP:0000848
29 hyperkalemia 56 32 Frequent (79-30%) HP:0002153
30 increased circulating acth level 56 32 Very frequent (99-80%) HP:0003154
31 orthostatic hypotension 56 32 Occasional (29-5%) HP:0001278
32 hyperpigmentation of the skin 56 32 Very frequent (99-80%) HP:0000953
33 primary ovarian failure 56 32 Occasional (29-5%) HP:0001587
34 normocytic anemia 56 32 Frequent (79-30%) HP:0001897
35 generalized bone demineralization 56 32 Occasional (29-5%) HP:0006462
36 decreased urinary potassium 56 32 Frequent (79-30%) HP:0012364
37 premature ovarian failure 56 32 Occasional (29-5%) HP:0008209
38 sparse axillary hair 56 32 Occasional (29-5%) HP:0002215
39 decreased female libido 56 32 Occasional (29-5%) HP:0030018
40 adrenal calcification 56 32 Occasional (29-5%) HP:0010512
41 androgen insufficiency 56 32 Frequent (79-30%) HP:0008226
42 hyperkalemic metabolic acidosis 56 32 Frequent (79-30%) HP:0005976
43 thiamine-responsive megaloblastic anemia 56 32 Very rare (<4-1%) HP:0004860
44 primary testicular failure 56 32 Very rare (<4-1%) HP:0008720
45 cyanosis 32 HP:0000961
46 vomiting 32 HP:0002013
47 hypotension 56 Very frequent (99-80%)
48 feeding difficulties in infancy 32 HP:0008872
49 abnormality of the cardiovascular system 32 HP:0001626
50 autoimmunity 56 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Addison's Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased transferrin (TF) endocytosis GR00363-A 9.32 CRH CTLA4 CYP11A1 CYP21A2 MC2R POMC

MGI Mouse Phenotypes related to Addison's Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.1 ABCD1 AIRE CRH CTLA4 CYP11A1 MC2R
2 behavior/neurological MP:0005386 10.09 ABCD1 AIRE CRH CYP11A1 CYP17A1 DDC
3 growth/size/body region MP:0005378 10.07 CRH CYP11A1 DDC MC2R POMC PTPN22
4 homeostasis/metabolism MP:0005376 10.07 ABCD1 AIRE CRH CTLA4 CYP11A1 CYP17A1
5 hematopoietic system MP:0005397 10.02 ABCD1 AIRE CRH CTLA4 CYP11A1 MC2R
6 immune system MP:0005387 9.9 AIRE CRH CTLA4 CYP11A1 DDC MC2R
7 liver/biliary system MP:0005370 9.43 POMC PTPN22 AIRE CRH CTLA4 CYP11A1
8 mortality/aging MP:0010768 9.36 STAR TPO AIRE CTLA4 CYP11A1 CYP17A1

Drugs & Therapeutics for Addison's Disease

Drugs for Addison's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 322)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 51-43-4 5816
2
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-23-7 5754 657311
3
Cortisone acetate Approved Phase 4 1950-04-4, 50-04-4 5745
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2 50-02-2 5743
5
Pravastatin Approved Phase 4,Phase 3 81093-37-0 54687
6
Lisinopril Approved, Investigational Phase 4 83915-83-7 5362119
7
Losartan Approved Phase 4 114798-26-4 3961
8
Nebivolol Approved, Investigational Phase 4,Phase 3 152520-56-4, 99200-09-6, 118457-14-0 71301
9
rituximab Approved Phase 4,Phase 3 174722-31-7 10201696
10
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
11
Menthol Approved Phase 4 2216-51-5 16666
12
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
13
Pitavastatin Approved Phase 4,Phase 3 147511-69-1, 147526-32-7 6366718 5282452
14
Cosyntropin Approved Phase 4 16960-16-0 16129617
15
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
16
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
17 tannic acid Approved, Nutraceutical Phase 4
18
Butyric Acid Experimental Phase 4,Phase 2,Phase 3,Phase 1 107-92-6 264
19
Cortisone Phase 4 53-06-5 222786
20 Atorvastatin Calcium Phase 4,Phase 3,Phase 2 134523-03-8
21 glucocorticoids Phase 4,Phase 2,Phase 3
22 Cortisol succinate Phase 4,Phase 2,Phase 3,Phase 1
23 Hormone Antagonists Phase 4,Phase 2,Phase 3
24 Hormones Phase 4,Phase 2,Phase 3
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
26 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 2,Phase 3,Phase 1
27 Hydrocortisone acetate Phase 4,Phase 2,Phase 3,Phase 1
28 Epinephryl borate Phase 4,Phase 3,Phase 2,Phase 1
29 Hydrocortisone-17-butyrate Phase 4,Phase 2,Phase 3,Phase 1
30 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3,Phase 2
31 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
32 Anticholesteremic Agents Phase 4,Phase 3,Phase 2
33 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
34 Racepinephrine Phase 4,Phase 3,Phase 2,Phase 1
35 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
36 Antimetabolites Phase 4,Phase 3,Phase 2
37 Calcium, Dietary Phase 4,Phase 3,Phase 2
38
Angiotensin II Phase 4,Phase 3 68521-88-0, 11128-99-7 65143 172198
39 Prednisolone acetate Phase 4
40 Dexamethasone acetate Phase 4,Phase 2 1177-87-3
41
protease inhibitors Phase 4,Phase 3,Phase 2
42 Mydriatics Phase 4,Phase 2,Phase 3,Phase 1
43 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1
44 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Phase 1
45 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
46 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3,Phase 1
47 Adrenergic beta-Agonists Phase 4,Phase 2,Phase 3,Phase 1
48 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
49 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
50 Dexamethasone 21-phosphate Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 170)
id Name Status NCT ID Phase
1 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Unknown status NCT02277587 Phase 4
2 Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions Unknown status NCT00640744 Phase 4
3 Trial to Assess the Effects of P-OM3 on LDL-C in Subjects With Primary Hypercholesterolemia Unknown status NCT00746811 Phase 4
4 Revival of Stem Cells in Addison's Study Completed NCT01371526 Phase 4
5 Test Predicting Adrenal Insufficiency in Volunteers Under Prednisone Treatment Completed NCT00975078 Phase 4
6 Rescue of Steroidogenic Capacity in Adrenocortical Failure Study (RADS) Completed NCT00753597 Phase 4
7 Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients Completed NCT00734630 Phase 4
8 A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects Completed NCT01301066 Phase 4
9 Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia Completed NCT01256476 Phase 4
10 Taper Or Abrupt Steroid Stop: TOASSTtrial Recruiting NCT03153527 Phase 4
11 Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia Unknown status NCT01229566 Phase 3
12 Glucocorticoid Treatment in Addison's Disease Completed NCT01063569 Phase 2, Phase 3
13 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency Completed NCT00004313 Phase 3
14 Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency Completed NCT00915343 Phase 2, Phase 3
15 Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) Completed NCT01235754 Phase 3
16 Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women Completed NCT00612742 Phase 3
17 Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women Completed NCT00613002 Phase 3
18 [E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL Completed NCT01408303 Phase 3
19 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Completed NCT00079274 Phase 3
20 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Completed NCT01764633 Phase 3
21 Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Completed NCT00326898 Phase 3
22 Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Completed NCT00041119 Phase 3
23 Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects Completed NCT02207634 Phase 3
24 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) Completed NCT02107196 Phase 3
25 Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood Completed NCT00616772 Phase 3
26 Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Completed NCT00693992 Phase 3
27 Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) Completed NCT01047501 Phase 3
28 Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment Completed NCT01363011 Phase 3
29 Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes Completed NCT00859898 Phase 3
30 Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002) Completed NCT01553747 Phase 3
31 Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001) Completed NCT01553591 Phase 3
32 Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes Completed NCT00821977 Phase 2, Phase 3
33 Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension Completed NCT01508026 Phase 3
34 Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes Completed NCT02648204 Phase 3
35 A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events Completed NCT01959529 Phase 3
36 Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients Completed NCT01422876 Phase 3
37 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus Completed NCT01370005 Phase 3
38 Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus Completed NCT00856284 Phase 3
39 Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery Completed NCT00683137 Phase 3
40 Epanova® for Lowering Very High Triglycerides II (EVOLVE II) Completed NCT02009865 Phase 3
41 Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL Completed NCT01047683 Phase 3
42 Epanova® for Lowering Very High Triglycerides Completed NCT01242527 Phase 2, Phase 3
43 A Study of S-033188 Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza Completed NCT02954354 Phase 3
44 A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back Completed NCT00671502 Phase 3
45 A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Completed NCT01880424 Phase 3
46 Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old Completed NCT01574612 Phase 3
47 (CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis Completed NCT00679432 Phase 3
48 Evaluation of an Oral Nutritional Supplement Containing AN777 Completed NCT01191125 Phase 3
49 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Completed NCT00045162 Phase 3
50 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Recruiting NCT01169337 Phase 3

Search NIH Clinical Center for Addison's Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: addison disease

Genetic Tests for Addison's Disease

Genetic tests related to Addison's Disease:

id Genetic test Affiliating Genes
1 Adrenal Hypoplasia 29

Anatomical Context for Addison's Disease

MalaCards organs/tissues related to Addison's Disease:

39
Adrenal Gland, Skin, Testes, Kidney, Thyroid, Bone, Pituitary

Publications for Addison's Disease

Articles related to Addison's Disease:

(show top 50) (show all 611)
id Title Authors Year
1
A Complex Interplay: Cognitive Behavioural Therapy for Severe Health Anxiety in Addison's Disease to Reduce Emergency Department Admissions. ( 28390450 )
2017
2
Mortality in patients with diabetes mellitus and Addison's disease: a nationwide, matched, observational cohort study. ( 27928991 )
2017
3
MANAGEMENT OF ENDOCRINE DISEASE: Regenerative therapies in autoimmune Addison's disease. ( 27810905 )
2017
4
Addison's Disease and Possible Cannabis Withdrawal Syndrome Presenting as an Eating Disorder in a Thirty-Year-Old Female. ( 28348901 )
2017
5
'Golden rules' for treating Addison's disease. ( 28082707 )
2017
6
Impaired quality and efficiency of sleep impairs cognitive functioning in Addison's disease. ( 28235729 )
2017
7
Addison's Disease and Dilated Cardiomyopathy: A Case Report and Review of the Literature. ( 28003914 )
2016
8
Sarcoidosis Presenting Addison's Disease. ( 27150885 )
2016
9
Erratum: First presentation of Addison's disease as hyperkalaemia in acute kidney injury. ( 27277582 )
2016
10
A rare case of Addison's disease, hepatitis, thyreoiditis, positive IgG anti-tissue transglutaminase antibodies and partial IgA deficiency. ( 27536208 )
2016
11
Supporting the treatment of Addison's disease in dogs. ( 27837079 )
2016
12
From Appearance of Adrenal Autoantibodies to Clinical Symptoms of Addison's Disease: Natural History. ( 27211204 )
2016
13
Polymorphisms of the GR and HSD11B1genes influence body mass index and weight gain during hormone replacement treatment in patients with Addison's disease. ( 26800219 )
2016
14
Maternal and neonatal outcomes of pregnancies in women with Addison's disease: a population-based cohort study on 7.7 million births. ( 27981742 )
2016
15
Polymorphic variants of the HSD11B1 gene may be involved in adverse metabolic effects of glucocorticoid replacement therapy in Addison's disease. ( 27083553 )
2016
16
Analysis of cellular and humoral immune responses against cytomegalovirus in patients with autoimmune Addison's disease. ( 26956521 )
2016
17
Extended exome sequencing identifies BACH2 as a novel major risk locus for Addison's disease. ( 27807919 )
2016
18
Addison's disease as a presentation of metastatic malignant melanoma. ( 26688417 )
2016
19
Impact of month-of-birth on the risk of development of autoimmune Addison's disease. ( 27575942 )
2016
20
Effect of steroid replacement on thyroid function and thyroid autoimmunity in Addison's disease with primary hypothyroidism. ( 27042409 )
2016
21
How best to treat Addison's disease in dogs? ( 27450847 )
2016
22
MAVS is not a Likely Susceptibility Locus for Addison's Disease and Type 1 Diabetes. ( 27652379 )
2016
23
Decreased physical activity, reduced QoL and presence of debilitating fatigue in patients with Addison's disease. ( 26953557 )
2016
24
Treatment of Addison's disease in dogs. ( 27103698 )
2016
25
A case of adrenoleukodystrophy presenting with manic symptoms in a patient on steroids for Addison's disease. ( 28197008 )
2016
26
A Variant in the BACH2 Gene Is Associated With Susceptibility to Autoimmune Addison's Disease in Humans. ( 27680876 )
2016
27
GPs face charges of manslaughter over boy's death from Addison's disease. ( 27153856 )
2016
28
First presentation of Addison's disease as hyperkalaemia in acute kidney injury. ( 27170604 )
2016
29
Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ( 27813051 )
2016
30
Positive autoantibodies to ZnT8 indicate elevated risk for additional autoimmune conditions in patients with Addison's disease. ( 26972575 )
2016
31
Management of Addison's disease in dogs. ( 27154940 )
2016
32
Clinical and immunological characteristics of Autoimmune Addison's disease: a nationwide Swedish multicenter study. ( 27870550 )
2016
33
Insights into Addison's disease in dogs. ( 27932737 )
2016
34
A rare case of Addison's disease due to bilateral adrenal histoplasmosis presenting with hypoglycaemia. ( 27727656 )
2016
35
Addison's disease with polyglandular autoimmunity carries a more than 2.5-fold risk for adrenal crises: German Health insurance data 2010-2013. ( 26896640 )
2016
36
Takotsubo-like syndrome triggered by fludrocortisone overdose for Addison's disease: a case report. ( 27729057 )
2016
37
A suspected case of Addison's disease in cattle. ( 26346956 )
2015
38
Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease. ( 26184416 )
2015
39
The acute effect of a mineralocorticoid receptor agonist on corticotrope secretion in Addison's disease. ( 26450146 )
2015
40
COEXISTENCE OF ADDISON'S DISEASE AND PERNICIOUS ANEMIA: IS THE NEW CLASSIFICATION OF AUTOIMMUNE POLYGLANDULAR SYNDROME APPROPRIATE? ( 26415323 )
2015
41
Autoantibodies against Cytochrome P450 Side-Chain Cleavage Enzyme in Dogs (Canis lupus familiaris) Affected with Hypoadrenocorticism (Addison's Disease). ( 26618927 )
2015
42
Hypoadrenocorticism (Addison's disease) in a Hoffmann's two-toed sloth (Choloepus hoffmanni). ( 25831596 )
2015
43
Linkage Analysis in Autoimmune Addison's Disease: NFATC1 as a Potential Novel Susceptibility Locus. ( 26042420 )
2015
44
Cognitive function in patients with primary adrenal insufficiency (Addison's disease) and the role of mineralocorticoid receptors. ( 26383398 )
2015
45
Severe hyponatraemia with absence of hyperkalaemia in rapidly progressive Addison's disease. ( 26021383 )
2015
46
Poor quality of life, depressed mood, and memory impairment may be mediated by sleep disruption in patients with Addison's disease. ( 26256520 )
2015
47
Hyponatremic rhabdomyolysis in Addison's disease in a child with autoimmune polyglandular syndrome type 2. ( 26300496 )
2015
48
Cognitive function in patients with primary adrenal insufficiency (Addison's disease). ( 25705797 )
2015
49
Recurrent nocturnal hypoglycaemia as a cause of morning fatigue in treated Addison's disease - favourable response to dietary management: a case report. ( 26500000 )
2015
50
The Role of Fludrocortisone in Cognition and Mood in Patients with Primary Adrenal Insufficiency (Addison's Disease). ( 26227663 )
2015

Variations for Addison's Disease

ClinVar genetic disease variations for Addison's Disease:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 ABCD1 NM_000033.3(ABCD1): c.1817C> T (p.Ser606Leu) single nucleotide variant Pathogenic rs128624225 GRCh37 Chromosome X, 153008477: 153008477
2 ABCD1 ABCD1, 1-BP DEL, 2204G deletion Pathogenic

Copy number variations for Addison's Disease from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17293 1 142400000 148000000 Deletion FCGR1C Addison''s disease

Expression for Addison's Disease

Search GEO for disease gene expression data for Addison's Disease.

Pathways for Addison's Disease

Pathways related to Addison's Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.95 CYP11A1 CYP21A2 MC2R STAR TPO
2 11.8 CRH MC2R POMC
3
Show member pathways
11.56 CYP11A1 MC2R POMC
4 11.32 CRH CYP11A1 CYP21A2 POMC STAR
5
Show member pathways
11.3 CYP11A1 CYP17A1 CYP21A2
6 11.13 CYP11A1 CYP17A1 STAR
7
Show member pathways
10.97 CYP11A1 CYP17A1 CYP21A2 POMC STAR
8
Show member pathways
10.76 CYP17A1 CYP21A2
9 10.21 CRH POMC

GO Terms for Addison's Disease

Cellular components related to Addison's Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 8.92 CRH CYP17A1 DDC STAR

Biological processes related to Addison's Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 steroid metabolic process GO:0008202 9.56 CRH CYP11A1 CYP17A1 CYP21A2
2 response to immobilization stress GO:0035902 9.48 CRH REN
3 response to corticosterone GO:0051412 9.46 CRH STAR
4 hormone biosynthetic process GO:0042446 9.43 CYP17A1 TPO
5 C21-steroid hormone biosynthetic process GO:0006700 9.4 CYP11A1 STAR
6 cellular response to alkaloid GO:0071312 9.37 DDC STAR
7 sterol metabolic process GO:0016125 9.33 CYP11A1 CYP17A1 CYP21A2
8 diterpenoid metabolic process GO:0016101 9.32 CRH STAR
9 steroid biosynthetic process GO:0006694 9.26 CYP11A1 CYP17A1 CYP21A2 STAR
10 glucocorticoid biosynthetic process GO:0006704 8.8 CRH CYP17A1 CYP21A2

Molecular functions related to Addison's Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 iron ion binding GO:0005506 9.33 CYP11A1 CYP17A1 CYP21A2
2 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.13 CYP11A1 CYP17A1 CYP21A2
3 heme binding GO:0020037 8.92 CYP11A1 CYP17A1 CYP21A2 TPO

Sources for Addison's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....